aDepartment of Environmental Health and Center for Environmental Genetics (CEG), University of Cincinnati Medical Center, Cincinnati, Ohio, USA
bDepartment of Biochemistry and Center in Molecular Toxicology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
cDivision of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska University Hospital-Huddinge, Karolinska Institutet, Stockholm, Sweden
dDivision of Molecular Toxicology, IMM, Karolinska Institutet, Stockholm, Sweden
eDivision of Pharmacogenomics and Molecular Epidemiology, National Center for Toxicological Research, Jefferson, Arkansas, USA
fPediatric Pharmacology Research Unit
gDivision of Child and Adolescent Psychiatry, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA
hDepartment of Clinical Pharmacology
iDivision of Drug Metabolism and Pharmacokinetics, ALTANA Pharma AG, Konstanz, Germany
Correspondence and requests for reprints to Daniel W. Nebert, Department of Environmental Health, University of Cincinnati Medical Center, PO Box 670056, Cincinnati OH 45267-0056, USA
Tel: +1 513 558 4347; fax: +1 513 558 3562;
e-mail [email protected]
Sponsorship: This study was supported, in part, by NIH Grants R01 CA90426 and P30 ES00267 (F.P.G.), U10 HD037249 (A.A.V., D.W.N.), and R01 ES08147 and P30 ES06096 (D.W.N.).
Received 19 October 2005 Accepted 15 December 2005
